Men's Health News

RSS

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

High intensity focused ultrasound provides important treatment for men with prostate cancer

For the estimated 220,000 men who will be diagnosed with prostate cancer this year, deciding on a method of treatment can be a challenge. Some with early-stage cancer pursue a "wait and watch" option, also called active surveillance, while others with more severe cancer immediately pursue surgery, including prostatectomy (removal of the prostate).

26 Jan 2016

Magnesium Flakes named ‘Best Sports’ product

A pioneering mineral bath soak has scooped the ‘Best Sports’ product accolade at the Natural Lifestyle Product Awards 2015.

From BetterYou Ltd 25 Jan 2016

MDxHealth recognized with 2015 Global Frost & Sullivan Award for Technology Innovation

Based on its recent analysis of the prostate cancer diagnostics market, Frost & Sullivan recognizes MDxHealth with the 2015 Global Frost & Sullivan Award for Technology Innovation. To advance molecular diagnostic tests for urological cancers, MDxHealth supplemented its prostate cancer test, ConfirmMDx, with a urine-based "liquid-biopsy" test called SelectMDx.

21 Jan 2016

Prostate cancer patients living in metropolitan areas more likely to be treated with radiation or surgery

A new study suggests that men with localized prostate cancer living in more highly populated areas are more likely to be treated with surgery or radiation compared to men residing in less populated areas.

21 Jan 2016

New imaging test detects prostate cancer much better than any other tests in use today

Researchers at Thomas Jefferson University have found the method they developed to image the prostate appears to be much better at detecting prostate cancer than any other test — radiographical, biopsy or blood — in use today.

20 Jan 2016

New report reveals striking variation in cancer burden within AANHPI population

A new report describes cancer among Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPIs), and reports striking variation in the cancer burden within this population, reflecting vast differences in exposure to cancer risk factors.

18 Jan 2016

Help beat the blues this Monday with a B12 Boost

Boost your mood and energy levels this Blue Monday (18 January) by topping up your vitamin B12, say natural health pioneers BetterYou.

From BetterYou Ltd 14 Jan 2016

Study opens new avenues for treatment of prostate cancer in obese patients

Obesity has direct consequences on health and is associated with the onset of aggressive cancers, but the mechanisms underlying this phenomenon are little known. Researchers from the Institut de Pharmacologie et he Biologie Structurale (CNRS/Université Toulouse III - Paul Sabatier) have recently elucidated one of these mechanisms in prostate cancer, one of the most common cancers in men: in obese patients, the adipose tissue surrounding the prostate gland facilitates the propagation of tumor cells outside the prostate.

13 Jan 2016

Cornell researchers identify potent cancer-killing proteins that can kill tumors in bloodstream

Cornell researchers have discovered potent cancer-killing proteins that can travel by white blood cells to kill tumors in the bloodstream of mice with metastatic prostate cancer. The breakthrough study will be published Feb. 10 as the cover article in the Journal of Controlled Release.

13 Jan 2016

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing.

11 Jan 2016

Cancer mortality continues to drop in the U.S.

Steady reductions in smoking combined with advances in cancer prevention, early detection, and treatment have resulted in a 23% drop in the cancer death rate since its peak in 1991. The drop translates to more than 1.7 million cancer deaths averted through 2012.

8 Jan 2016

Biocept introduces blood-based test for detection, monitoring of prostate cancer and breast cancer

Biocept, Inc., a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient's blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer.

7 Jan 2016

Men not having important discussions with health providers about prostate cancer screening, treatment

Researchers at the University of Nebraska Medical Center and the University of Memphis recently published an article in the American Journal of Men's Health which found that men and their health providers are not having important discussions when it comes to prostate cancer screening and treatment.

7 Jan 2016

Study supports argument that declining PSA screening may lead to avoidable cancer deaths

The U.S. Preventive Services Task Force recommendation against regular prostate specific antigen (PSA) screening for prostate cancer (PCa) has been in place for two and a half years. Although the number of prostate needle biopsies (PNB) has been reduced, patients who undergo PNB are significantly more likely to be diagnosed with high risk disease, and detection of intermediate risk, potentially curable PCa has likely decreased.

6 Jan 2016

New study finds familial risk and heritability of cancer among twins

A large new study of twins has found that having a twin sibling diagnosed with cancer poses an excess risk for the other twin to develop any form of cancer. Among the 23 different types of cancer studied, an excess familial risk was seen for almost all of the cancers, including common cancers such as breast and prostate cancer, but also more rare cancers such as testicular cancer, head and neck cancer, melanoma, ovarian and stomach cancer.

6 Jan 2016

Exercise training could be a new treatment for prostate cancer

A newly-launched Cancer Research UK study could be the first step towards exercise training being introduced as a new NHS treatment for prostate cancer.

6 Jan 2016

African American men with prostate cancer have significantly lower PSA density than Caucasian men

A new study published in The Journal of Urology revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs.

5 Jan 2016

Study: Prostate surgery patients have unrealistic expectations regarding postoperative sexual function

Patients who have undergone radical prostatectomy often have largely unrealistic expectations with regard to their postoperative sexual function, new research shows.

4 Jan 2016

High diversity among circulating tumor cells predicts survival, treatment resistance in prostate cancer patients

Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only shorter overall survival, but also the development of resistance to key anti-androgen therapies.

4 Jan 2016

Men's Health News

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

High intensity focused ultrasound provides important treatment for men with prostate cancer

Magnesium Flakes named ‘Best Sports’ product

MDxHealth recognized with 2015 Global Frost & Sullivan Award for Technology Innovation

Prostate cancer patients living in metropolitan areas more likely to be treated with radiation or surgery

New imaging test detects prostate cancer much better than any other tests in use today

New report reveals striking variation in cancer burden within AANHPI population

Help beat the blues this Monday with a B12 Boost

Study opens new avenues for treatment of prostate cancer in obese patients

Cornell researchers identify potent cancer-killing proteins that can kill tumors in bloodstream

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

Cancer mortality continues to drop in the U.S.

Biocept introduces blood-based test for detection, monitoring of prostate cancer and breast cancer

Men not having important discussions with health providers about prostate cancer screening, treatment

Study supports argument that declining PSA screening may lead to avoidable cancer deaths

New study finds familial risk and heritability of cancer among twins

Exercise training could be a new treatment for prostate cancer

African American men with prostate cancer have significantly lower PSA density than Caucasian men

Study: Prostate surgery patients have unrealistic expectations regarding postoperative sexual function

High diversity among circulating tumor cells predicts survival, treatment resistance in prostate cancer patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News